Discover Andy Brown's long and arduous journey battling a type of non-Hodgkin lymphoma and how a clinical trial altered his ...

See why investor confidence in cell and gene therapies now depends on execution and supply chain strategy—not strong science ...

Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and ...

The companies Moderna, Amylyx Pharmaceuticals, and Braveheart Bio bagged the biggest biotech funding rounds overall in August ...

Cytokinetics’ aficamten has become the first cardiac myosin inhibitor to succeed in a phase 3 trial in non-obstructive hypertrophic cardiomyopathy (HCM), potentially opening a new treatment option for ...